Drug Profile
Research programme: DNA-based cancer immunotherapies - OncoSec Medical
Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator OncoSec Medical
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Gene transference; Interleukin 12 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 24 Nov 2020 OncoSec Medical in-licenses Cliniporator® electroporation technology from IGEA Clinical Biophysics
- 27 May 2020 OncoSec Medical receives patent allowance for patent application covering immunotherapies and electroporation gene delivery system for the treatment of Cancer in Canada and Europe